The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC related information was provided by the message!
  • No CSPEC computer assertion could be determined for this classification!

  • See Evidence submitted by expert panel for details.

Variant: NM_000018.4(ACADVL):c.830AGA[1] (p.Lys278del)

CA8337864

281042 (ClinVar)

Gene: ACADVL
Condition: very long chain acyl-CoA dehydrogenase deficiency
Inheritance Mode: Autosomal recessive inheritance
UUID: c999a197-cea5-4a05-8665-02a16f020996

HGVS expressions

NM_000018.4:c.833_835delAGA
NM_000018.4:c.833_835del
NM_000018.4:c.830AGA[1]
NM_000018.4(ACADVL):c.830AGA[1] (p.Lys278del)
NC_000017.11:g.7222257_7222259del
CM000679.2:g.7222257_7222259del
NC_000017.10:g.7125576_7125578del
CM000679.1:g.7125576_7125578del
NC_000017.9:g.7066300_7066302del
NG_007975.1:g.7424_7426del
NG_008391.2:g.2795_2797del
ENST00000356839.10:c.833_835del
ENST00000322910.9:c.*788_*790del
ENST00000350303.9:c.767_769del
ENST00000356839.9:c.833_835del
ENST00000543245.6:c.902_904del
ENST00000577191.5:n.1005_1007del
ENST00000581378.5:c.551_553del
ENST00000582379.1:n.217_219del
NM_000018.3:c.833_835del
NM_001033859.2:c.767_769del
NM_001270447.1:c.902_904del
NM_001270448.1:c.605_607del
NM_001033859.3:c.767_769del
NM_001270447.2:c.902_904del
NM_001270448.2:c.605_607del

Likely Pathogenic

Met criteria codes 4
PM2_Supporting PM3 PM4 PP4_Moderate

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
ACADVL VCEP
The NM_000018.4 c.833_835del (p.Lys278del) variant in ACADVL is an in-frame deletion (removes amino acids Lys278) in exon 9/20 that is not predicted to impact splicing (SpliceAI: 0.01). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001 in African/African American population, which is lower than the ClinGen ACADVL Variant Curation Expert Panel threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). The c.833_835del variant is predicted to cause a change in the length of the protein (p.Lys278del) due to an in-frame deletion of an amino acid in a non-repeat region (PM4). This variant is reported in the literature in multiple individuals affected with very long-chain acyl-CoA dehydrogenase deficiency in both compound heterozygous and homozygous fashion, with at least one of whom displayed elevated C14:1 carnitine level (1.3 µmol/L) and reduced VLCAD enzyme levels (17% WT control), which is highly specific for VLCAD deficiency (PP4_Moderate, PMID: 19327992). This patient also carried a pathogenic variant c.1376G>A in trans (PM3 score = 1.0, PM3, PMID: 19327992). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal recessive very long chain acyl-CoA dehydrogenase (VLCAD) deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: PM2_Supporting, PM4, PP4_Moderate, PM3 (ACADVL VCEP specifications version 1; approved November 9, 2021).
Met criteria codes
PM2_Supporting
The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001 in African/African American population, which is lower than the ClinGen ACADVL Variant Curation Expert Panel threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting).
PM3
a pathogenic variant c.1376G>A in trans (PM3 score = 1.0, PM3, PMID: 19327992).
PM4
The c.833_835del variant is predicted to cause a change in the length of the protein (p.Lys278del) due to an in-frame deletion of an amino acid in a non-repeat region (PM4).
PP4_Moderate
This variant is reported in the literature in multiple individuals affected with very long-chain acyl-CoA dehydrogenase deficiency in both compound heterozygous and homozygous fashion, with at least one of whom displayed elevated C14:1 carnitine level (1.3 µmol/L) and reduced VLCAD enzyme levels (17% WT control), which is highly specific for VLCAD deficiency (PP4_Moderate, PMID: 19327992).
Approved on: 2024-05-16
Published on: 2024-05-16
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.